Lakewood-Amedex Biotherapeutics Inc.
LABTDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Bisphosphocin Nu-3 | Phase 2 | Diabetic Foot Infections | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Lakewood-Amedex Biotherapeutics Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Lakewood-Amedex Biotherapeutics Inc.'s (LABT) pipeline across Phase 2. Its lead program is Bisphosphocin Nu-3 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Lakewood-Amedex Biotherapeutics Inc.'s next FDA catalyst?→
Lakewood-Amedex Biotherapeutics Inc.'s (LABT) next tracked catalyst is a Earnings expected November 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track LABT biotech catalysts?→
Add LABT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Lakewood-Amedex Biotherapeutics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.